First day of Eid Al Adha expected to be on this date
The Islamic world will observe the crescent moon of Dhu al-Hijjah 1446 AH on Tuesday, May 27, 2025 AD. The crescent moon can be seen with a telescope in Central and Western Asia, most of Africa, and Europe, and with the naked eye in large parts of the Americas.
Since the crescent moon can be seen in the Islamic world on Tuesday, Wednesday, May 28, is expected to be the first day of Dhu al-Hijjah, and Friday, June 6, will be the first day of Eid Al Adha in most Islamic countries.
Regarding the position of the crescent moon on Tuesday, May 27, in some Arab and international cities, the surface calculations of the crescent moon at sunset are as follows: In Jakarta, the moon sets 9 minutes after sunset, at an age of 9 hours and 2 minutes. The crescent moon cannot be seen in Jakarta even with a telescope. In Abu Dhabi, the moon sets 38 minutes after sunset, at an age of 13 hours and 29 minutes, and its distance from the sun is 7.7 degrees.
In Mecca, the moon sets 39 minutes after sunset, at 14 hours and 17 minutes, and its distance from the sun is 8.1 degrees. The crescent moon can only be seen with a telescope in Abu Dhabi and Mecca.
In Amman and Jerusalem, the moon sets 48 minutes after sunset, at a age of 14 hours and 46 minutes, and its distance from the sun is 8.4 degrees. In Cairo, the moon sets 47 minutes after sunset, at an age of 14 hours and 54 minutes, and its distance from the sun is 8.5 degrees. In Rabat, the moon sets 58 minutes after sunset, at 17 hours, and its distance from the sun is 9.9 degrees. Seeing the crescent moon in Amman, Jerusalem, Cairo, and Rabat is difficult with the naked eye and requires very clear skies.
To understand the meaning of these numbers, it is worth noting that the shortest period of a crescent that could be seen with the naked eye was 29 minutes, while the shortest age of a crescent that could be seen with the naked eye was 15 hours and 33 minutes. It is not sufficient for the crescent to be longer than these values for it to be seen, as the sighting of the crescent is related to other factors such as its angular distance from the sun and its distance from the horizon at the time of observation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times of Oman
3 days ago
- Times of Oman
First successful CAR-T Cell therapy for cancer patients in Oman
Muscat: The University Medical City, represented by the National Centre for the Treatment of Blood Diseases and Bone Marrow Transplantation, has successfully implemented the first Chimeric Antigen Receptor T-cell (CAR-T) therapy in the Sultanate of Oman, utilising national medical personnel and international partnerships. This achievement marks a pioneering medical milestone, positioning Oman among regional leaders in providing advanced and precision treatments for blood cancer patients. CAR-T cell therapy is one of the latest immunotherapies, where T-cells are extracted from the patient, genetically modified, and then reinfused to precisely target cancer cells. The treatment has shown remarkable response rates in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL), particularly for those unresponsive to conventional therapies. Dr. Ibrahim Mohammed Al Nabhani, Assistant Professor at Sultan Qaboos University's College of Medicine and Health Sciences and Consultant Hematologist specializing in lymphoma and cellular therapy at the University Medical City, stated that this accomplishment reflects the rapid advancement of Oman's healthcare sector in biomedical innovation. He emphasised that this high-efficacy treatment, previously limited to select international centers, now offers hope to patients and their families at the University Medical City in Oman. In his turn, Dr. Murtadha Khamis Al Khabouri from Sultan Qaboos University's College of Medicine and Health Sciences, Senior Consultant in Hematology and Head of the Hematology Department at the University Medical City, explained that the therapy's implementation resulted from collaboration between the lymphoma and myeloid oncology team, bone marrow transplantation, and cellular therapy at the National Centre for Blood Diseases and Bone Marrow Transplantation, the Ministry of Health's Overseas Treatment Department, and academic partners from the Fortis Memorial Research Institute. The goal is to localise cutting-edge medical technologies, establish a national center for advanced therapies, and translate research into clinical applications. Meanwhile, Dr. Sultan Salim Al Harthi, Director of the Overseas Treatment Department at the Ministry of Health, highlighted that this treatment is part of key programs to localise specialised care, easing patient burdens and delivering top-tier medical services within Oman. By introducing CAR-T therapy through the University Medical City, Oman takes a step toward medical self-sufficiency and cost reduction compared to overseas referrals, supported by substantial investments in national workforce training and global collaborations to ensure compliance with international standards.
Times of Oman
10-08-2025
- Times of Oman
Oman's skies to witness peak of Perseid meteor shower on Tuesday
Muscat: The skies of Oman are currently graced by the Perseid meteor shower, visible to the naked eye across various governorates—particularly in dark locations away from light pollution. The phenomenon, which continues until 24 August, will reach its peak from Tuesday evening until the early hours of Wednesday morning. It is one of the most captivating astronomical events for stargazers and astrophotography enthusiasts worldwide.
Times of Oman
03-08-2025
- Times of Oman
Omani research team uses AI to detect genetic heart disorders
Muscat: A groundbreaking research initiative has made significant progress in identifying the genetic causes of cardiomyopathy in the Sultanate of Oman. The study, titled 'Implementation of Machine Learning Approach to Predict Pathogenicity of Genetic Variants Associated with Cardiomyopathy,' utilises Whole Exome Sequencing (WES) and advanced Artificial Intelligence (AI) methodologies to investigate the underlying genetic contributors to this complex heart condition. The research was led by Dr. Ahmed Al Amri, Consultant of Molecular Genetics Lab and Head of Training and Professional Staff Development at the National Genetics Centre of the Royal Hospital. Cardiomyopathy, a heterogeneous group of myocardial disorders, remains a significant health burden worldwide. In the Sultanate of Oman, the genetic basis of the disease has been insufficiently characterised, hindering effective diagnosis and intervention. This study aimed to bridge that gap by conducting genetic analysis on a cohort of Omani families affected by cardiomyopathy. Dr. Ahmed Al Amri explained that central to the research is the development of a novel AI-based analysis model called 'CardioVar.' This model is designed to enhance the interpretation of WES data through the integration of more than 50,000 genetic variants and mutations linked to cardiomyopathy, supported by multiple AI algorithms to ensure analytical precision. The research project achieved a diagnostic success rate of over 80%, uncovering both known and previously unreported genetic mutations, some of which involve genes not previously linked to cardiomyopathy. These findings offer valuable insight into the genetic landscape of the disease within the Omani population and present new opportunities for further research to confirm the clinical relevance of novel variants. The AI model significantly improved both the speed and accuracy of genetic analysis, demonstrating its practical value in overcoming the limitations of traditional sequencing approaches. Dr. Al Amri emphasised that this approach not only advances the understanding of the genetic basis of cardiomyopathy in the Sultanate of Oman but also provides a scalable framework for implementing AI in genomic medicine, enhancing diagnostic accuracy and personalised care. The multidisciplinary research team included Dr. Ahmed Al Amri, Dr. Aisha Al Balushi, Nibras Al Mahrami, Dr. Musallam Al Ariami, Dr. Nadia Al Hashimi, Dr. Mohammed Al Rawahi, Dr. Tuqa Al Lawati, Dr. Bushra Al Shamsi, Dr. Fahad Al Hattali, and Ms. Mashael Al Balushi. Together, they have contributed to a practical model that blends clinical knowledge, laboratory science, and artificial intelligence to achieve high-impact results. This research not only advances the scientific understanding of inherited cardiomyopathy in the Sultanate of Oman but also exemplifies how AI can transform genetic diagnostics. It stands as a national model for the integration of precision medicine into routine clinical care, with plans to expand the study to include other hereditary heart conditions and incorporate its findings into everyday healthcare practices.
